Somatuline Depot Approval History

• FDA approved: Yes (First approved August 30th, 2007)
• Brand name: Somatuline Depot
• Generic name: lanreotide acetate
• Previous name: Somatuline Autogel
• Company: Tercica, Inc.
• Treatment for: Acromegaly

Somatuline Depot is a sustained-release injection formulation of lanreotide, a somatostatin analogue indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.

FDA Approval History for Somatuline Depot

Date	Article
Aug 31, 2007	Ipsen: Somatuline Depot Receives Marketing Approval in the United States for the Treatment of Acromegaly
Jan 15, 2007	FDA Accepts for Filing a New Drug Application (NDA) for Somatuline Autogel
Nov  2, 2006	Tercica Reports Somatuline Autogel NDA for Acromegaly Submitted to FDA

See also...

Somatuline Depot (lanreotide acetate) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.